The bioequivalence is defined for a generic in relation to a brand-name drug. This mistake can sometimes be seen in the medical literature, however, with incorrect extrapolations. ![]() Hence, it is wrong to consider that there is a -20% to + 25% variation in the AUC (and thus in the bioavailability) between a generic and a brand-name drug. This interval applies to the 90% CI of the ratios of the AUC (or Cmax) and not directly to the ratio of their values. the upper and lower limits of the 90% confidence interval (90% CI) of the generic-to-brand ratio for the area under the curve (AUC) and for the maximum plasma concentration (Cmax) are included in the interval. Two drugs are considered bioequivalent if. This lack of clarity may be an obstacle to their use. Because the scientific aspects of bioequivalence that govern the use of generics are sometimes described ambiguously in the literature, they are not always perceived clearly by health professionals. ![]() The market share of generic drugs in France is quite low compared to that in other European countries.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |